Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asston Pharmaceuticals's earnings before interest and taxes (EBIT) for the
six
months ended in Mar. 2026 was ₹49.2 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹52.3 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Asston Pharmaceuticals's annualizedROC % for the quarter that ended in Mar. 2026 was -11.52%.
Asston Pharmaceuticals's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 28.32%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Asston Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.59%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Asston Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asston Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Asston Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Asston Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹52.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asston Pharmaceuticals (BOM:544445) has a EBIT of ₹52.3 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Asston Pharmaceuticals.
Is Asston Pharmaceuticals' EBIT too high?
Asston Pharmaceuticals' current EBIT is ₹52.3 Mil. Overall, Asston Pharmaceuticals has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Asston Pharmaceuticals' EBIT compare to ZTS?
Asston Pharmaceuticals' EBIT of ₹52.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Asston Pharmaceuticals. Asston Pharmaceuticals's current EBIT is ₹52.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asston Pharmaceuticals stock overvalued right now?
Asston Pharmaceuticals (BOM:544445) has a current EBIT of ₹52.3 Mil. The current EBIT is ₹52.3 Mil. Asston Pharmaceuticals' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Asston Pharmaceuticals (BOM:544445), the current EBIT is ₹52.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Asston Pharmaceuticals Ltd manufactures and exports pharmaceutical and nutraceutical products. The company produces a wide range of healthcare items including tablets, capsules, syrups, sachets, ointments, creams, gels, and lotions. It serves markets in West and South Africa, with expansions planned into Asian countries. Asston conducts business through export sales, contract manufacturing and loan license arrangements via merchant exporters, and domestic sales within India. Revenue is generated through the sale of branded and generic pharmaceutical formulations along with nutraceutical products. The business operations are broadly categorized into: Domestic Formulations, Export Formulations, APIs and Intermediates, and Research and Development.
19GF Score
Get the complete analysis for BOM:544445
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544445 has been successfully added to your 
